The five month old GPCR Consortium – which brings together industry and academics to explore the G protein- coupled receptors (GPCRs) family of proteins – has added two new pharmaceutical members to its fold. It now counts Novo Nordisk AS and Merck & Co. Inc. as members in addition to founding members Amgen Inc., Ono Pharmaceutical Co. Ltd. and Sanofi SA. The partners provide not just funding to the research consortium’s efforts. They help ensure the basic research being conducted in the academic sites is directed to pharmaceutically relevant targets for cancer, diabetes and mental disorders.
Read the full article in BioWorld Today here.